Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 9/2008

01-11-2008 | Original Paper

Ethnic differences in prostate cancer survival in New Zealand: a national study

Author: Mary Jane Sneyd

Published in: Cancer Causes & Control | Issue 9/2008

Login to get access

Abstract

Objective

To examine disease-specific survival from prostate cancer by ethnic group in New Zealand.

Methods

Analyses were based on the 7,733 men with histologically confirmed prostate cancer diagnosed from the start of 1996 to the end of 1999 in New Zealand. Five-year adjusted prostate-specific mortality rates and hazard ratios were calculated for Maori, Pacific, and European men.

Results

In univariate analyses, Maori and Pacific men had higher mortality particularly in the first year after a diagnosis of prostate cancer than did European men. The strongest prognostic factors for prostate cancer were Gleason score and age. When survival analyses by ethnic group were adjusted for age and Gleason score the disparities in survival for Maori men and Pacific men with low-grade prostate cancers remained, with European men having the best survival.

Conclusions

Several possible explanations have been proposed to explain the survival disparities by ethnicity in New Zealand. Differentials in Gleason grade of disease by ethnic group explain a lot of these disparities. Further data on stage of disease at diagnosis, co-morbidity, treatment, access to health services, and behavioral and environmental factors are needed to resolve these issues.
Footnotes
1
New Zealanders can choose to identify with more than one ethnic group so totals do not add up to 100%.
 
Literature
1.
New Zealand Health Information Service (2007) Cancer: new registrations and deaths 2004. NZHIS, Wellington
2.
Robbins AS, Yin D, Parikh-Patel A (2007) Differences in prognostic factors and survival among white men and black men with prostate cancer, California, 1995–2004. Am J Epidemiol 166:71–78PubMedCrossRef
3.
Tewari A, Horninger W, Pelzer A et al (2005) Factors contributing to the racial differences in prostate cancer mortality. BJU Int 96:1247–1252PubMedCrossRef
4.
Ilmonen S, Asko-Seljavaara S, Kariniemi A-L, Jeskanen L, Pyrhönen S, Muhonen T (2002) Prognosis of primary melanoma. Scand J Surg 91:166–171PubMed
5.
International Agency for Research on Cancer (1990) Patterns of cancer in five continents. IARC Sci Publ 120:1–129
6.
Robson B, Purdie G, Cormack D (2006) Unequal impact: Maori and non-Maori cancer statistics 1996–2001. Te Ropu Rangahau Hauora a Eru Pomare, Wellington
7.
Cox B, Sneyd M, Paul C, Delahunt B, Skegg D (2002) Vasectomy and risk of prostate cancer. J Am Med Assoc 287:3110–3115CrossRef
8.
Pocock S, Clayton T, Altman D (2002) Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 359:1686–1689PubMedCrossRef
9.
Cox D (1972) Regression models and life-tables (with discussion). J R Stat Soc Ser B 34:187–220
10.
Lancelot R, Lesnoff M, McDermott J (2002) Use of Akaike information criteria for model selection and inference. An application to assess prevention of gastrointestinal parasitism and respiratory mortality of Guinean goats in Kolda, Senegal. Prev Vet Med 55:217–240PubMedCrossRef
11.
StataCorp (2005) Stata statistical software: release 9. StataCorp LP, College Station, TX
12.
StataCorp (2007) Stata statistical software: release 10. StataCorp LP, College Station, TX
13.
Cormack D, Robson B, Purdie G, Ratima M, Brown R (2005) Access to cancer services for Maori: a report prepared for the Ministry of Health. Ministry of Health, Wellington
14.
Ajwani S, Blakely T, Robson B, Tobias M, Bonne M (2003) Decades of disparity: ethnic mortality trends in New Zealand 1980–1999. Ministry of Health, Wellington
15.
New Zealand Health Information Service (2005) Mortality and demographic data 2001. NZHIS, Wellington
16.
New Zealand Health Information Service (2006) Cancer: new registrations and deaths 2002. NZHIS, Wellington
17.
New Zealand Health Information Service (2007) Cancer: new registrations and deaths 2003. NZHIS, Wellington
18.
New Zealand Health Information Service (2006) Cancer patient survival: covering the period 1994–2003. Ministry of Health, Wellington
19.
Jeffreys M, Stevanovic V, Tobias M, Lewis C (2005) Ethnic inequalities in cancer survival in New Zealand: linkage study. Am J Public Health 95:834–837PubMedCrossRef
20.
Capocaccia R, Gatta G, Roazzi P et al (2003) The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis. Ann Oncol 15:v14–v27CrossRef
21.
Bach P, Schrag D, Brawley O, Galaznik A, Yakren S, Begg C (2002) Survival of blacks and whites after a cancer diagnosis. J Am Med Assoc 287:2106–2113CrossRef
22.
Godley P, Schenck A, Amamoo M et al (2003) Racial differences in mortality among medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst 95:1702–1710PubMed
23.
Cohen J, Schoenbach V, Kaufman J et al (2006) Racial differences in clinical progression among Medicare recipients after treatment for localized prostate cancer (United States). Cancer Causes Control 17:803–811PubMedCrossRef
24.
Ministry of Health (2004) A portrait of health: key results of the 2002/2003 New Zealand Health Survey. Ministry of Health, Wellington
25.
Ministry of Health (2004) The health and independence report 2004: Director-General of Health’s annual report on the state of public health. Ministry of Health, Wellington
26.
Stevens W, Stevens G, Kolbe J, Cox B (2008) Ethnic differences in the management of lung cancer in New Zealand. J Thorac Oncol 3:237–244PubMedCrossRef
27.
Schaaf NF (2008) An investigation of delay in diagnosis of cancer in the Pacific Island men living in New Zealand. MPH Thesis: University of Otago
28.
Ministry of Health (2004) Cervical cancer audit report: screening of women with cervical cancer, 2000–2002. Cervical Cancer Audit, University of Auckland, Auckland
29.
Shavers V, Brown M (2002) Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 94:334–357PubMed
Metadata
Title
Ethnic differences in prostate cancer survival in New Zealand: a national study
Author
Mary Jane Sneyd
Publication date
01-11-2008
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 9/2008
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-008-9166-1

Other articles of this Issue 9/2008

Cancer Causes & Control 9/2008 Go to the issue

Original Paper

Association of the TCF7L2 polymorphism with colorectal cancer and adenoma risk

Original Paper

Physical activity, sedentary behavior, and the risk of colon and rectal cancer in the NIH-AARP Diet and Health Study

Original Paper

Variants in hormone biosynthesis genes and risk of endometrial cancer

Original Paper

Influence of body mass index on prognosis in gynecological malignancies

Original Paper

Social inequalities in the incidence and case fatality of cancers of the lung, the stomach, the bowels, and the breast

Letter to the editor

Systemic folate status and risk of colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits